Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
The late-stage pipeline for the common condition of overactive bladder may be sparse, but the early-to-mid stage pipeline holds potential for new treatment options in the future – and the population is growing.
Overactive bladder refers to the frequent need to urinate – more than eight times per day or more than once...
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
